Heron Therapeutics announces second-quarter financial results
Click Here to Manage Email Alerts
Key takeaways:
- Heron Therapeutics Inc. announced its second-quarter financial results.
- The company reported $36 million in net product sales and $25.5 million in gross profit for the quarter.
Heron Therapeutics Inc. announced increased net product sales and gross profit in its second quarter of 2024 financial results, according to a company press release.
Heron Therapeutics reported net product sales of $36 million for second quarter of 2024, an increase from the prior year period. The company also reported gross profit of $25.5 million for the quarter, an increase from the prior year period.
“We have had an exciting start to 2024 with many encouraging milestones that provide the foundation for ongoing commercial success,” Craig Collard, CEO of Heron Therapeutics, said in the release. “We are improving the financial efficiency of the business by growing revenues, improving margins, and reducing expenses. Regarding Zynrelef, we continue to expand our partnership with CrossLink and progress our regulatory activities in anticipation of a fourth quarter launch of the [Zynrelef vial access needle] VAN.”
According to the release, Heron Therapeutics announced a Prescription Drug User Fee Act goal date of Sept. 23 for Zynrelef VAN.
Read more about
Click Here to Manage Email Alerts